Multiple Sclerosis

November 2003
PharmaWatch: CNS;November 2003, Vol. 2 Issue 11, p17
Market Research Report
Reports on developments relating to multiple sclerosis (MS) treatment. Phase II of Active Biotech's multiple sclerosis drug; Positive long-term results for MS patients shown by Serono's Rebif drug; Study showing long-term effect of Biogen's MS drug.


Related Articles

  • Orphan Competition.  // Pharmaceutical Executive;Apr2002, Vol. 22 Issue 4, p24 

    Focuses on the approval won by Geneva, Switzerland-based Serono to market its multiple sclerosis (MS) therapy, Rebif, in the U.S. Impact of the approval on the stock of Biogen's MS drug Avonex in the U.S.

  • MEDICINE BY MANDARINS. Gottlieb, Scott // American Spectator;Nov/Dec2002, Vol. 35 Issue 6, p22 

    Deals with the issue of the way the drug developed by Biogen for the treatment of multiple sclerosis, was manufactured. Clinical experience with the drug; Issue in the early 1990s when a group of Food and Drug Administration statisticians arbitrarily tightened the metrics for assessing new...

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p5 

    The author reflects on the gap that exists in the orally administered treatments for relapsing multiple sclerosis (MS). He asserts that laquinomoid, an autoimmune suppressant used for treating relapsing MS, is behind from other oral MS treatments in the clinical trial process. He stresses that...

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p15 

    The article reports on the positive result of the test of laquinimod, an oral disease modifying treatment for multiple sclerosis. Phase III clinical trials are initiated by Teva and Swedish biotech partner Active Biotech AB. It is stated that laquinimod is expected to become the fifth oral...

  • Teva and Active Biotech amend marketing and distribution agreement.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p5 

    No abstract available.

  • Teva and Active Biotech announce fast track status for multiple sclerosis drug.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p12 

    The article reports on the announcement made by Teva Pharmaceutical Industries, a generic pharmaceutical company and Sweden-based pharmaceutical company Active Biotech on the fast track designation given by the Food and Drug Administration to the oral laquinimod in the U.S. It cites that oral...

  • Other News To Note.  // BioWorld International;7/25/2012, Vol. 17 Issue 30, p5 

    This section offers news briefs on the pharmaceutical industry. Active Biotech of Lund, Sweden said that the European Medicines Agency has finished the validation process for the marketing authorization application for laquinimod in relapsing remitting multiple sclerosis. Celgene International...

  • Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that Teva Pharmaceutical Industries Ltd. and Active Biotech AB are to initiate a third Phase III study of laquinimod, following the written agreement reached with the U.S. Food & Drug Administration (FDA) on the Special Protocol Assessment (SPA). The third Phase III...

  • Daclizumab approved for some forms of multiple sclerosis. Chamberlin, Kevin W.; Whalley, Adam S. // Drug Topics;Oct2016, Vol. 160 Issue 10, p24 

    The article reports that on May 27, 2016 the U.S. Food and Drug Administration (FDA) announced the approval of Zinbryta (daciizumab) by Biogen Inc. for the treatment of adults with relapsing forms of multiple sclerosis (MS). The effects of daciizumab during pregnancy and lactation of humans has...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics